The AI landscape doesn't move in one direction — it lurches. Some techniques leap from experiment to table stakes in a single quarter; others stall against regulatory walls, technical ceilings, or organisational inertia that no amount of hype can dislodge. Knowing which is which is the hard part. The State of Play cuts through the noise with a rigorously maintained index of AI techniques across every major business domain — classified by maturity, evidenced by real-world adoption, and updated daily so you always know where you stand relative to the field. Stop guessing. Start knowing.
A daily newsletter distilling the past two weeks of movement in a domain or two — delivered to your inbox while the index updates in the background.
Each dot marks the weighted maturity of practices within a domain — hover for a brief summary, click for more detail
AI-controlled rehabilitation robots, assistive devices, prosthetics, and exoskeletons that adapt to user movement and intent. Includes neural-interface prosthetics and adaptive gait training; distinct from surgical robotics which operates in clinical rather than rehabilitative settings.
Rehabilitation, assistive, and prosthetic robotics has cleared every traditional gate to mainstream adoption -- regulatory approval across three regions, operational insurance reimbursement, and clinical evidence from multi-centre RCTs -- yet remains a leading-edge practice confined to well-resourced institutions and individually funded home users. The technology works: AI-controlled exoskeletons train gait in stroke and spinal cord injury patients (though meta-analysis evidence shows no superiority to conventional therapy for ambulatory function), neural-interface prosthetics decode motor intent with over 96% accuracy, and brain-computer interfaces are producing clinically meaningful results in chronic stroke recovery. China's regulatory approval of Neuracle Medical Technology's implantable BCI for hand movement (March 2026) marks the first commercial BCI clearance for prosthetic control, expanding the field beyond US institutions. Three major Medicare Advantage insurers now cover personal exoskeletons, reaching roughly 16 million beneficiaries, with Good Shepherd Rehabilitation achieving 500,000+ cumulative steps in Wandercraft Atalante X deployment. July 2026 updates confirm portable exoskeleton effectiveness for the first time in real-world conditions: a University of Utah hip exoskeleton demonstrated 18% metabolic cost reduction in stroke hemiparesis, validated across diverse populations and preserved in post-device use. Japan's government announced formal reimbursement pre-screening for ISO-certified lower-limb exoskeletons effective October 2026, signaling major-developed-economy mainstream adoption readiness. Consumer market expansion continues with Haier's 1.75kg W3 achieving 1,000+ units sold monthly at $2,200 price. Emerging-market cost reduction pathways are emerging: an India-based startup reduced exoskeleton costs to Rs 5–20 lakhs (10× less than imports) via modular ML-based design, with documented patient recovery from spinal cord injury. However, structural adoption barriers remain unresolved. Major US payers continue rejecting coverage: Blue Cross North Carolina maintains FDA-cleared exoskeletons as "investigational" despite 12 years of regulatory clearances, exemplifying gaps between regulatory approval and payer adoption. Ekso Bionics, the category's largest institutional vendor, exited medical robotics entirely (May 2026 merger with AI infrastructure firm). Chronic BCI deployment faces a fundamental engineering barrier: signal degradation via glial scarring over weeks-to-months despite passing safety tests, as expert assessments confirm standard toxicity testing does not validate long-term functionality. The defining tension is not whether these systems deliver clinical value -- the evidence is strong -- but whether the economics, implementation complexity, and unresolved engineering barriers can support deployment at scale beyond the vanguard.
The exoskeleton vendor landscape is consolidating and fragmenting simultaneously. Ekso Bionics completed merger into AI infrastructure firm (ChronoScale Corporation) in May 2026—effectively exiting medical robotics despite holding 400+ facility deployments, reflecting fundamental market viability constraints. Lifeward (formerly ReWalk) is moving in the opposite direction, commercialising the ReWalk 7 with cloud connectivity and acquiring Skelable's AI-powered upper-body exoskeleton for stroke rehabilitation. Wandercraft has deployed nearly 100 Atalante X units across the US, Europe, and Brazil, with Good Shepherd Rehabilitation (Philadelphia) reaching 500,000+ cumulative steps in 2026 (documented at ASIA 2026 conference with 13-year longitudinal safety data showing zero fractures in German cohort since 2018). Roam Robotics deployed soft pneumatic exoskeletons via military partnerships (US Navy SEALs, USAF), VA testing, and Rush University clinical trials (osteoarthritis knee indication with 46% pain reduction). The consumer market is emerging: Haier's W3 exoskeleton (1.75kg, ¥15,999/$2,200) sold 1,000+ units in June 2026 launch month with government subsidy eligibility in Shandong province, signaling market transition from clinical-only to affordable home use for elderly mobility assistance. Six FDA/CE-approved commercial exoskeletons remain on the market, but vendor economics remain precarious. Emerging-market vendors are differentiating on cost: Indian startup Astrek's modular ML-based exoskeleton achieved 10× cost reduction (Rs 5–20 lakhs vs. Rs 1.2 crore for imports) and is deployed across multiple rehabilitation facilities with documented patient functional recovery from spinal cord injury. Clinical partnerships are expanding: Lifeward partnered with Shirley Ryan AbilityLab (ranked #1 US rehabilitation hospital) in March 2026; Northwestern University and Shirley Ryan published June 2026 Science Robotics study on therapist-exoskeleton paired systems (TEPI) showing greater ROM and step metrics vs. conventional training; separate Northwestern Nature Communications study documented 18% walking energy cost reduction via selective hip-assistance design.
Reimbursement expansion is geographically divergent and fragmented. US Medicare established a $94,617 lump-sum payment (January 2024); by April 2026, Aetna, Humana, and UnitedHealthcare grant coverage to approximately 16 million Medicare Advantage beneficiaries with <30-day processing. However, major US commercial payers remain obstructive: Blue Cross North Carolina (and similar regional carriers covering millions) maintain FDA-cleared exoskeletons in "investigational" classification, denying coverage despite 12 years of regulatory clearances (2014–2026)—evidence that regulatory approval does not drive payer adoption. Japan announced formal reimbursement pre-screening effective October 2026, covering up to 72% cost for ISO-certified lower-limb exoskeletons in home and outpatient settings, signaling major-developed-economy reclassification from experimental to mainstream. An Administrative Law Judge ruling (June 2025) established US legal precedent for medical necessity. Evidence-based clinical decision-making is maturing: subgroup analysis in Journal of Rehabilitation Medicine found different predictors of success (timing for conventional training, cognitive function for robotic training), suggesting exoskeletons extend the rehabilitation window for cognitively intact patients.
Brain-computer interfaces have reached a regulatory inflection point but face persistent technical barriers. China's National Medical Products Administration approved Neuracle Medical Technology's implantable BCI (NEO) for hand movement control in March 2026—the world's first commercial BCI clearance for prosthetic function, with 36 procedures conducted at 11 Chinese hospitals; patient Dong Hui regained ability to write his name after 11 months of daily training. May 2026 evidence consolidates BCI maturity: CorTec's Brain Interchange platform demonstrated dual capability (therapeutic cortical stimulation for stroke recovery plus thought-controlled computer use) on same implanted device in NIH-funded UW trial; BrainCo's non-invasive commercial prosthetics achieved cost parity (1/5 to 1/7 of Western devices) across 35+ countries with 2,000 units fitted in China and government policy reimbursement support; Paradromics gained IDE approval for BCI speech-restoration trial across multiple academic centers (UC Davis, MGH, U. Michigan). July 2026 long-term safety data published in Science Translational Medicine strengthen the case: decade-long implant study across 5 SCI patients delivered 168 million electrical pulses with zero serious adverse events, with Poisson analysis yielding per-pulse safety ceiling of 1.79×10⁻⁸ and 64% electrode longevity at study end (13.6-year half-life projection), establishing critical regulatory precedent for chronic BCIs. BrainGate typing neuroprosthesis achieved 22 words/minute with 1.6% error rate in home-use trials. Neural-interface prosthetics are advancing: machine-learning-driven RPNI control achieved over 96% accuracy, soft hand exoskeletons with EMG intent detection (97% sensitivity) restored dexterous grasping in severe ALS cases with patients regaining ability to feed themselves, and osseointegrated mechanoneural prostheses demonstrated improved walking and embodiment. However, persistent technical barriers constrain adoption. Long-term signal degradation via glial scarring and immune response—despite passing standard toxicity tests—remains unresolved: standard biocompatibility testing checks one-time toxicity, not two-year functionality, creating a fundamental chronicity validation gap. Average device costs of $42,800 and documented user concerns about reliability, safety, and social acceptance keep adoption narrow. Material engineering advances (PDMS coatings for neural implants) are addressing durability but cannot yet prevent signal loss at clinical scale. Emerging indications are expanding: systematic review of exoskeleton efficacy in pediatric cerebral palsy (21 studies, 241 children) shows positive outcomes; RAGT feasibility in Guillain-Barré Syndrome shows positive outcomes but identifies adoption barriers (technology anxiety, psychological factors). Critical assessment: A 2026 multicenter RCT showed exoskeleton-assisted gait training was NOT superior to conventional rehabilitation for primary ambulatory function outcomes, though secondary improvements in lower-limb strength were observed—challenging claims of broad therapeutic superiority. Leading exoskeleton researchers identified unverified claims in sim-to-real transfer research, with reported results violating physiological limits and algorithmic implementations unavailable for verification; critical commentary highlights translation gap between single-session lab feasibility studies and multi-month controlled trials required for clinical adoption, indicating persistent maturity gaps in ML-driven control systems and research credibility.
— Industry analysis identifies adoption bottleneck: cleared devices still fail in clinical settings due to regulatory fragmentation, limited clinical evidence, weak post-market surveillance, absent reimbursement pathways—documents structural barriers separate from technology maturity; winners (Myomo, Lifeward) demonstrate reimbursement-plus-registration discipline.
— Commercial product launch of Neuvotion's NeuStim NN-01 (wearable neuromuscular stimulator for hand recovery in stroke/C5 SCI) with simultaneous Nature Medicine peer-review validation; represents rare product-GA milestone paired with clinical trial publication.
— REEV's DREEVEN pivotal clinical trial underway at Boston University, Encompass Health Braintree, and Whittier Rehabilitation Hospital; FDA-regulated pathway with SENSE gait analysis platform enabling clinical evidence generation for motorized ankle-foot orthosis in post-stroke gait impairment.
— Meta-analysis of 15 RCTs (n=659 middle-aged acute stroke survivors) demonstrates large effect sizes (SMD 0.84–0.92) for motor recovery and gait stability via body-weight-supported robotic gait training versus conventional therapy; validates clinical efficacy in acute neuroplasticity window.
— ARCSA regulatory approval in Ecuador for Wandercraft's Atalante X self-balancing exoskeleton; now deployed at 150+ inpatient and outpatient rehabilitation centers worldwide with geographic expansion into Latin America; demonstrates mature international clinical deployment at scale.
— Neuracle's NEO (epidural BCI + pneumatic robotic glove for hand function restoration in cervical SCI) received NHSA reimbursement billing code within 48 hours of March 2026 NMPA approval—first invasive motor BCI approved for routine clinical use; demonstrates healthcare system adoption integration.
— Major US commercial payer (Blue Cross NC) maintains classification of FDA-cleared exoskeletons as investigational, denying all coverage despite 12 years of regulatory clearances (2014–2026)—critical evidence that regulatory approval does not drive payer adoption at commercial insurance level.
— Science Translational Medicine decade-long study: 168 million electrical pulses across 5 SCI patients over 27 patient-years with zero serious adverse events; Poisson safety ceiling 1.79×10⁻⁸; 64% electrode longevity with 13.6-year half-life projection—establishing regulatory pathway for chronic bidirectional BCIs.